#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-5	White	_
1-2	6-12	matter	_
1-3	13-20	changes	_
1-4	21-23	in	_
1-5	24-33	treatment	_
1-6	34-44	refractory	_
1-7	45-58	schizophrenia	_
1-8	59-60	:	_
1-9	61-65	Does	_
1-10	66-75	cognitive	_
1-11	76-83	control	_
1-12	84-87	and	_
1-13	88-99	myelination	_
1-14	100-106	matter	_
1-15	107-108	?	_

2-1	109-119	Widespread	_
2-2	120-125	white	_
2-3	126-132	matter	_
2-4	133-146	abnormalities	_
2-5	147-151	have	_
2-6	152-156	been	_
2-7	157-165	reported	_
2-8	166-168	in	_
2-9	169-182	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-10	183-184	,	_
2-11	185-186	a	_
2-12	187-195	disorder	_
2-13	196-206	frequently	_
2-14	207-220	characterised	_
2-15	221-223	as	_
2-16	224-225	a	_
2-17	226-239	dysconnection	_
2-18	240-248	syndrome	_
2-19	249-250	.	_

3-1	251-256	White	_
3-2	257-263	matter	_
3-3	264-276	connectivity	_
3-4	277-279	in	_
3-5	280-293	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-6	294-297	has	_
3-7	298-302	been	_
3-8	303-316	predominantly	_
3-9	317-329	investigated	_
3-10	330-335	using	_
3-11	336-345	diffusion	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
3-12	346-354	weighted	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
3-13	355-362	imaging	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
3-14	363-364	,	_
3-15	365-369	with	_
3-16	370-380	reductions	_
3-17	381-383	in	_
3-18	384-394	fractional	_
3-19	395-405	anisotropy	_
3-20	406-416	throughout	_
3-21	417-420	the	_
3-22	421-426	brain	_
3-23	427-432	often	_
3-24	433-444	interpreted	_
3-25	445-447	as	_
3-26	448-450	an	_
3-27	451-460	indicator	_
3-28	461-463	of	_
3-29	464-472	abnormal	_
3-30	473-484	myelination	_
3-31	485-486	.	_

4-1	487-494	However	_
4-2	495-496	,	_
4-3	497-506	diffusion	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
4-4	507-515	weighted	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
4-5	516-523	imaging	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
4-6	524-529	lacks	_
4-7	530-541	specificity	_
4-8	542-545	and	_
4-9	546-548	as	_
4-10	549-553	such	_
4-11	554-555	a	_
4-12	556-562	number	_
4-13	563-565	of	_
4-14	566-581	microstructural	_
4-15	582-589	factors	_
4-16	590-597	besides	_
4-17	598-604	myelin	_
4-18	605-608	may	_
4-19	609-611	be	_
4-20	612-624	contributing	_
4-21	625-627	to	_
4-22	628-633	these	_
4-23	634-641	results	_
4-24	642-643	.	_

5-1	644-646	We	_
5-2	647-655	utilised	_
5-3	656-670	multicomponent	_
5-4	671-677	driven	_
5-5	678-689	equilibrium	_
5-6	690-696	single	_
5-7	697-702	pulse	_
5-8	703-714	observation	_
5-9	715-717	of	_
5-10	718-720	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
5-11	721-724	and	_
5-12	725-727	T2	_
5-13	728-729	(	_
5-14	730-738	mcDESPOT	_
5-15	739-740	)	_
5-16	741-743	in	_
5-17	744-753	medicated	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-18	754-762	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-19	763-767	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-20	768-775	chronic	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-21	776-789	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-22	790-791	,	_
5-23	792-802	stratified	_
5-24	803-805	by	_
5-25	806-815	treatment	_
5-26	816-824	response	_
5-27	825-831	status	_
5-28	832-833	,	_
5-29	834-837	and	_
5-30	838-845	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-31	846-854	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-32	855-856	,	_
5-33	857-859	in	_
5-34	860-865	order	_
5-35	866-868	to	_
5-36	869-875	assess	_
5-37	876-882	myelin	_
5-38	883-888	water	_
5-39	889-897	fraction	_
5-40	898-899	(	_
5-41	900-903	MWF	_
5-42	904-905	)	_
5-43	906-908	in	_
5-44	909-914	these	_
5-45	915-921	groups	_
5-46	922-923	.	_

6-1	924-926	In	_
6-2	927-935	addition	_
6-3	936-937	,	_
6-4	938-940	we	_
6-5	941-949	assessed	_
6-6	950-959	cognitive	_
6-7	960-967	control	_
6-8	968-973	using	_
6-9	974-977	the	_
6-10	978-984	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
6-11	985-989	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
6-12	990-992	to	_
6-13	993-1004	investigate	_
6-14	1005-1008	how	_
6-15	1009-1017	response	_
6-16	1018-1028	inhibition	_
6-17	1029-1036	relates	_
6-18	1037-1039	to	_
6-19	1040-1051	myelination	_
6-20	1052-1054	in	_
6-21	1055-1063	patients	_
6-22	1064-1067	and	_
6-23	1068-1076	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-24	1077-1078	.	_

7-1	1079-1083	Both	_
7-2	1084-1093	treatment	_
7-3	1094-1103	resistant	_
7-4	1104-1105	(	_
7-5	1106-1107	n	_
7-6	1108-1109	=	_
7-7	1110-1112	22	_
7-8	1113-1114	)	_
7-9	1115-1118	and	_
7-10	1119-1128	treatment	_
7-11	1129-1139	responsive	_
7-12	1140-1141	(	_
7-13	1142-1143	n	_
7-14	1144-1145	=	_
7-15	1146-1148	21	_
7-16	1149-1150	)	_
7-17	1151-1159	patients	_
7-18	1160-1166	showed	_
7-19	1167-1174	reduced	_
7-20	1175-1178	MWF	_
7-21	1179-1187	compared	_
7-22	1188-1190	to	_
7-23	1191-1198	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-24	1199-1207	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-25	1208-1209	(	_
7-26	1210-1211	n	_
7-27	1212-1213	=	_
7-28	1214-1216	24	_
7-29	1217-1218	)	_
7-30	1219-1221	in	_
7-31	1222-1231	bilateral	_
7-32	1232-1248	fronto-occipital	_
7-33	1249-1258	fasciculi	_
7-34	1259-1260	,	_
7-35	1261-1273	particularly	_
7-36	1274-1281	evident	_
7-37	1282-1284	in	_
7-38	1285-1288	the	_
7-39	1289-1297	vicinity	_
7-40	1298-1300	of	_
7-41	1301-1304	the	_
7-42	1305-1313	striatum	_
7-43	1314-1317	und	_
7-44	1318-1327	extending	_
7-45	1328-1330	to	_
7-46	1331-1334	the	_
7-47	1335-1345	cerebellum	_
7-48	1346-1347	,	_
7-49	1348-1352	with	_
7-50	1353-1355	no	_
7-51	1356-1366	difference	_
7-52	1367-1374	between	_
7-53	1375-1382	patient	_
7-54	1383-1389	groups	_
7-55	1390-1391	.	_

8-1	1392-1400	Patients	_
8-2	1401-1407	showed	_
8-3	1408-1415	greater	_
8-4	1416-1424	reaction	_
8-5	1425-1429	time	_
8-6	1430-1442	interference	_
8-7	1443-1445	on	_
8-8	1446-1449	the	_
8-9	1450-1456	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
8-10	1457-1461	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
8-11	1462-1470	compared	_
8-12	1471-1473	to	_
8-13	1474-1481	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-14	1482-1490	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-15	1491-1492	,	_
8-16	1493-1497	with	_
8-17	1498-1500	no	_
8-18	1501-1511	difference	_
8-19	1512-1519	between	_
8-20	1520-1527	patient	_
8-21	1528-1534	groups	_
8-22	1535-1536	.	_

9-1	1537-1543	Stroop	_
9-2	1544-1556	interference	_
9-3	1557-1560	was	_
9-4	1561-1574	significantly	_
9-5	1575-1585	negatively	_
9-6	1586-1596	correlated	_
9-7	1597-1601	with	_
9-8	1602-1605	MWF	_
9-9	1606-1608	in	_
9-10	1609-1612	the	_
9-11	1613-1619	corpus	_
9-12	1620-1628	callosum	_
9-13	1629-1635	across	_
9-14	1636-1642	groups	_
9-15	1643-1644	,	_
9-16	1645-1648	and	_
9-17	1649-1652	MWF	_
9-18	1653-1664	differences	_
9-19	1665-1667	in	_
9-20	1668-1672	this	_
9-21	1673-1679	region	_
9-22	1680-1688	mediated	_
9-23	1689-1692	the	_
9-24	1693-1704	behavioural	_
9-25	1705-1710	group	_
9-26	1711-1718	effects	_
9-27	1719-1721	on	_
9-28	1722-1725	the	_
9-29	1726-1732	Stroop	_
9-30	1733-1737	task	_
9-31	1738-1739	.	_

10-1	1740-1745	These	_
10-2	1746-1754	findings	_
10-3	1755-1762	support	_
10-4	1763-1766	the	_
10-5	1767-1778	suitability	_
10-6	1779-1781	of	_
10-7	1782-1790	mcDESPOT	_
10-8	1791-1793	as	_
10-9	1794-1795	a	_
10-10	1796-1811	myelin-specific	_
10-11	1812-1819	measure	_
10-12	1820-1822	of	_
10-13	1823-1831	abnormal	_
10-14	1832-1844	connectivity	_
10-15	1845-1847	in	_
10-16	1848-1861	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-17	1862-1863	,	_
10-18	1864-1867	and	_
10-19	1868-1875	suggest	_
10-20	1876-1880	that	_
10-21	1881-1890	treatment	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
10-22	1891-1900	resistant	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
10-23	1901-1914	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
10-24	1915-1917	is	_
10-25	1918-1921	not	_
10-26	1922-1935	characterised	_
10-27	1936-1938	by	_
10-28	1939-1943	more	_
10-29	1944-1950	severe	_
10-30	1951-1964	abnormalities	_
10-31	1965-1967	in	_
10-32	1968-1979	myelination	_
10-33	1980-1982	or	_
10-34	1983-1992	cognitive	_
10-35	1993-2000	control	_
10-36	2001-2009	compared	_
10-37	2010-2012	to	_
10-38	2013-2022	treatment	_
10-39	2023-2033	responsive	_
10-40	2034-2047	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-41	2048-2049	.	_

11-1	2050-2060	Highlights	_
11-2	2061-2070	Treatment	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
11-3	2071-2080	resistant	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
11-4	2081-2084	and	_
11-5	2085-2095	responsive	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-6	2096-2109	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-7	2110-2118	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-8	2119-2123	show	_
11-9	2124-2131	reduced	_
11-10	2132-2138	myelin	_
11-11	2139-2144	water	_
11-12	2145-2153	fraction	_
11-13	2154-2162	compared	_
11-14	2163-2165	to	_
11-15	2166-2173	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-16	2174-2182	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-17	2183-2189	Myelin	_
11-18	2190-2195	water	_
11-19	2196-2204	fraction	_
11-20	2205-2207	in	_
11-21	2208-2211	the	_
11-22	2212-2218	corpus	_
11-23	2219-2227	callosum	_
11-24	2228-2230	is	_
11-25	2231-2238	related	_
11-26	2239-2241	to	_
11-27	2242-2253	performance	_
11-28	2254-2256	on	_
11-29	2257-2258	a	_
11-30	2259-2268	cognitive	_
11-31	2269-2276	control	_
11-32	2277-2281	task	_
11-33	2282-2288	Myelin	_
11-34	2289-2294	water	_
11-35	2295-2303	fraction	_
11-36	2304-2306	in	_
11-37	2307-2310	the	_
11-38	2311-2317	corpus	_
11-39	2318-2326	callosum	_
11-40	2327-2335	mediates	_
11-41	2336-2347	differences	_
11-42	2348-2350	in	_
11-43	2351-2352	a	_
11-44	2353-2362	cognitive	_
11-45	2363-2370	control	_
11-46	2371-2375	task	_
11-47	2376-2383	between	_
11-48	2384-2392	patients	_
11-49	2393-2396	and	_
11-50	2397-2405	controls	_
11-51	2406-2414	Material	_
11-52	2415-2418	and	_
11-53	2419-2426	methods	_
11-54	2427-2439	Participants	_
11-55	2440-2443	The	_
11-56	2444-2449	study	_
11-57	2450-2458	included	_
11-58	2459-2461	43	_
11-59	2462-2473	individuals	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-60	2474-2478	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-61	2479-2480	a	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-62	2481-2490	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-63	2491-2493	of	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-64	2494-2507	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-65	2508-2509	(	_
11-66	2510-2519	according	_
11-67	2520-2522	to	_
11-68	2523-2529	ICD-10	_
11-69	2530-2538	criteria	_
11-70	2539-2540	)	_
11-71	2541-2544	and	_
11-72	2545-2547	24	_
11-73	2548-2555	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-74	2556-2564	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-75	2565-2572	matched	_
11-76	2573-2576	for	_
11-77	2577-2580	age	_
11-78	2581-2582	,	_
11-79	2583-2586	sex	_
11-80	2587-2588	,	_
11-81	2589-2592	and	_
11-82	2593-2606	socioeconomic	_
11-83	2607-2617	background	_
11-84	2618-2619	.	_

12-1	2620-2623	The	_
12-2	2624-2631	patient	_
12-3	2632-2638	sample	_
12-4	2639-2647	included	_
12-5	2648-2650	22	_
12-6	2651-2659	patients	_
12-7	2660-2663	who	_
12-8	2664-2673	fulfilled	_
12-9	2674-2682	criteria	_
12-10	2683-2686	for	_
12-11	2687-2696	treatment	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
12-12	2697-2707	resistance	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
12-13	2708-2709	(	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
12-14	2710-2713	TRS	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
12-15	2714-2715	)	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
12-16	2716-2717	,	_
12-17	2718-2723	based	_
12-18	2724-2726	on	_
12-19	2727-2729	at	_
12-20	2730-2735	least	_
12-21	2736-2739	two	_
12-22	2740-2745	prior	_
12-23	2746-2750	drug	_
12-24	2751-2757	trials	_
12-25	2758-2760	of	_
12-26	2761-2764	4–6	_
12-27	2765-2770	weeks	_
12-28	2771-2779	duration	_
12-29	2780-2784	with	_
12-30	2785-2787	no	_
12-31	2788-2796	clinical	_
12-32	2797-2808	improvement	_
12-33	2809-2810	,	_
12-34	2811-2822	persistence	_
12-35	2823-2825	of	_
12-36	2826-2833	illness	_
12-37	2834-2837	for	_
12-38	2838-2844	longer	_
12-39	2845-2849	than	_
12-40	2850-2854	five	_
12-41	2855-2860	years	_
12-42	2861-2865	with	_
12-43	2866-2868	no	_
12-44	2869-2875	period	_
12-45	2876-2878	of	_
12-46	2879-2883	good	_
12-47	2884-2890	social	_
12-48	2891-2893	or	_
12-49	2894-2906	occupational	_
12-50	2907-2918	functioning	_
12-51	2919-2920	,	_
12-52	2921-2924	and	_
12-53	2925-2935	persistent	_
12-54	2936-2945	psychotic	_
12-55	2946-2954	symptoms	_
12-56	2955-2957	as	_
12-57	2958-2965	defined	_
12-58	2966-2968	as	_
12-59	2969-2970	a	_
12-60	2971-2976	score	_
12-61	2977-2979	of	_
12-62	2980-2982	at	_
12-63	2983-2988	least	_
12-64	2989-2990	4	_
12-65	2991-2992	(	_
12-66	2993-3001	moderate	_
12-67	3002-3003	)	_
12-68	3004-3006	on	_
12-69	3007-3009	at	_
12-70	3010-3015	least	_
12-71	3016-3019	two	_
12-72	3020-3028	positive	_
12-73	3029-3036	symptom	_
12-74	3037-3042	items	_
12-75	3043-3045	of	_
12-76	3046-3049	the	_
12-77	3050-3058	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
12-78	3059-3062	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
12-79	3063-3071	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
12-80	3072-3080	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
12-81	3081-3086	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
12-82	3087-3088	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
12-83	3089-3094	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
12-84	3095-3096	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
12-85	3097-3098	.	_

13-1	3099-3102	The	_
13-2	3103-3112	remaining	_
13-3	3113-3115	21	_
13-4	3116-3124	patients	_
13-5	3125-3134	fulfilled	_
13-6	3135-3143	criteria	_
13-7	3144-3147	for	_
13-8	3148-3153	being	_
13-9	3154-3156	in	_
13-10	3157-3168	symptomatic	_
13-11	3169-3178	remission	_
13-12	3179-3180	(	_
13-13	3181-3194	non-treatment	_
13-14	3195-3204	resistant	_
13-15	3205-3206	;	_
13-16	3207-3210	NTR	_
13-17	3211-3212	)	_
13-18	3213-3214	,	_
13-19	3215-3217	as	_
13-20	3218-3225	defined	_
13-21	3226-3228	by	_
13-22	3229-3230	a	_
13-23	3231-3236	score	_
13-24	3237-3239	of	_
13-25	3240-3241	3	_
13-26	3242-3244	or	_
13-27	3245-3249	less	_
13-28	3250-3252	on	_
13-29	3253-3256	all	_
13-30	3257-3262	items	_
13-31	3263-3265	of	_
13-32	3266-3269	the	_
13-33	3270-3275	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
13-34	3276-3277	,	_
13-35	3278-3281	and	_
13-36	3282-3287	these	_
13-37	3288-3296	symptoms	_
13-38	3297-3303	having	_
13-39	3304-3308	been	_
13-40	3309-3315	stable	_
13-41	3316-3319	for	_
13-42	3320-3322	at	_
13-43	3323-3328	least	_
13-44	3329-3330	6	_
13-45	3331-3337	months	_
13-46	3338-3339	.	_

14-1	3340-3343	The	_
14-2	3344-3347	two	_
14-3	3348-3355	patient	_
14-4	3356-3362	groups	_
14-5	3363-3367	were	_
14-6	3368-3375	matched	_
14-7	3376-3379	for	_
14-8	3380-3383	age	_
14-9	3384-3385	,	_
14-10	3386-3389	sex	_
14-11	3390-3391	,	_
14-12	3392-3400	duration	_
14-13	3401-3403	of	_
14-14	3404-3411	illness	_
14-15	3412-3413	,	_
14-16	3414-3424	medication	_
14-17	3425-3429	type	_
14-18	3430-3433	and	_
14-19	3434-3440	dosage	_
14-20	3441-3442	.	_

15-1	3443-3450	Current	_
15-2	3451-3460	clozapine	_
15-3	3461-3464	use	_
15-4	3465-3468	was	_
15-5	3469-3471	an	_
15-6	3472-3481	exclusion	_
15-7	3482-3491	criterion	_
15-8	3492-3495	for	_
15-9	3496-3499	all	_
15-10	3500-3508	patients	_
15-11	3509-3510	;	_
15-12	3511-3515	this	_
15-13	3516-3519	was	_
15-14	3520-3522	to	_
15-15	3523-3531	maintain	_
15-16	3532-3535	the	_
15-17	3536-3547	homogeneity	_
15-18	3548-3550	of	_
15-19	3551-3554	the	_
15-20	3555-3562	patient	_
15-21	3563-3569	sample	_
15-22	3570-3571	-	_
15-23	3572-3582	fulfilling	_
15-24	3583-3586	the	_
15-25	3587-3595	standard	_
15-26	3596-3604	criteria	_
15-27	3605-3608	for	_
15-28	3609-3618	treatment	_
15-29	3619-3629	resistance	_
15-30	3630-3631	-	_
15-31	3632-3640	avoiding	_
15-32	3641-3644	the	_
15-33	3645-3657	introduction	_
15-34	3658-3660	of	_
15-35	3661-3671	sub-groups	_
15-36	3672-3674	of	_
15-37	3675-3683	patients	_
15-38	3684-3694	refractory	_
15-39	3695-3697	to	_
15-40	3698-3707	clozapine	_
15-41	3708-3709	(	_
15-42	3710-3725	super-resistant	_
15-43	3726-3734	patients	_
15-44	3735-3736	)	_
15-45	3737-3738	.	_

16-1	3739-3753	Chlorpromazine	_
16-2	3754-3755	(	_
16-3	3756-3759	CPZ	_
16-4	3760-3761	)	_
16-5	3762-3772	equivalent	_
16-6	3773-3778	doses	_
16-7	3779-3781	of	_
16-8	3782-3793	medications	_
16-9	3794-3798	were	_
16-10	3799-3809	calculated	_
16-11	3810-3815	using	_
16-12	3816-3826	conversion	_
16-13	3827-3833	tables	_
16-14	3834-3835	.	_

17-1	3836-3845	Exclusion	_
17-2	3846-3854	criteria	_
17-3	3855-3858	for	_
17-4	3859-3862	all	_
17-5	3863-3871	subjects	_
17-6	3872-3876	were	_
17-7	3877-3878	a	_
17-8	3879-3886	history	_
17-9	3887-3889	of	_
17-10	3890-3902	neurological	_
17-11	3903-3910	illness	_
17-12	3911-3912	,	_
17-13	3913-3920	current	_
17-14	3921-3926	major	_
17-15	3927-3935	physical	_
17-16	3936-3943	illness	_
17-17	3944-3945	,	_
17-18	3946-3949	and	_
17-19	3950-3954	drug	_
17-20	3955-3965	dependency	_
17-21	3966-3970	over	_
17-22	3971-3974	the	_
17-23	3975-3979	last	_
17-24	3980-3983	six	_
17-25	3984-3990	months	_
17-26	3991-3992	.	_

18-1	3993-4002	Exclusion	_
18-2	4003-4011	criteria	_
18-3	4012-4015	for	_
18-4	4016-4018	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-5	4019-4023	were	_
18-6	4024-4025	a	_
18-7	4026-4033	history	_
18-8	4034-4036	of	_
18-9	4037-4048	psychiatric	_
18-10	4049-4056	illness	_
18-11	4057-4060	and	_
18-12	4061-4062	a	_
18-13	4063-4075	first-degree	_
18-14	4076-4084	relative	_
18-15	4085-4094	currently	_
18-16	4095-4097	or	_
18-17	4098-4108	previously	_
18-18	4109-4118	suffering	_
18-19	4119-4123	from	_
18-20	4124-4125	a	_
18-21	4126-4135	psychotic	_
18-22	4136-4143	illness	_
18-23	4144-4145	.	_

19-1	4146-4149	All	_
19-2	4150-4158	subjects	_
19-3	4159-4162	had	_
19-4	4163-4169	normal	_
19-5	4170-4177	hearing	_
19-6	4178-4181	and	_
19-7	4182-4188	normal	_
19-8	4189-4191	or	_
19-9	4192-4211	corrected-to-normal	_
19-10	4212-4218	vision	_
19-11	4219-4220	.	_

20-1	4221-4232	Demographic	_
20-2	4233-4248	characteristics	_
20-3	4249-4252	and	_
20-4	4253-4261	clinical	_
20-5	4262-4266	data	_
20-6	4267-4270	are	_
20-7	4271-4280	presented	_
20-8	4281-4283	in	_
20-9	4284-4289	Table	_
20-10	4290-4291	1	_
20-11	4292-4293	.	_

21-1	4294-4301	Ethical	_
21-2	4302-4310	approval	_
21-3	4311-4314	was	_
21-4	4315-4323	provided	_
21-5	4324-4326	by	_
21-6	4327-4330	the	_
21-7	4331-4337	London	_
21-8	4338-4348	Camberwell	_
21-9	4349-4351	St	_
21-10	4352-4357	Giles	_
21-11	4358-4366	Research	_
21-12	4367-4370	and	_
21-13	4371-4377	Ethics	_
21-14	4378-4387	Committee	_
21-15	4388-4389	.	_

22-1	4390-4393	All	_
22-2	4394-4406	participants	_
22-3	4407-4415	provided	_
22-4	4416-4424	informed	_
22-5	4425-4432	written	_
22-6	4433-4440	consent	_
22-7	4441-4444	and	_
22-8	4445-4449	were	_
22-9	4450-4461	compensated	_
22-10	4462-4465	for	_
22-11	4466-4471	their	_
22-12	4472-4476	time	_
22-13	4477-4480	and	_
22-14	4481-4487	travel	_
22-15	4488-4489	.	_

23-1	4490-4493	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-2	4494-4505	acquisition	_
23-3	4506-4509	and	_
23-4	4510-4520	processing	_
23-5	4521-4526	Scans	_
23-6	4527-4531	were	_
23-7	4532-4540	acquired	_
23-8	4541-4543	on	_
23-9	4544-4545	a	_
23-10	4546-4548	3T	http://maven.renci.org/NeuroBridge/neurobridge#II
23-11	4549-4551	GE	http://maven.renci.org/NeuroBridge/neurobridge#II
23-12	4552-4558	Excite	http://maven.renci.org/NeuroBridge/neurobridge#II
23-13	4559-4561	II	http://maven.renci.org/NeuroBridge/neurobridge#II
23-14	4562-4564	MR	http://maven.renci.org/NeuroBridge/neurobridge#II
23-15	4565-4572	scanner	http://maven.renci.org/NeuroBridge/neurobridge#II
23-16	4573-4574	(	_
23-17	4575-4577	GE	_
23-18	4578-4588	Healthcare	_
23-19	4589-4590	,	_
23-20	4591-4594	USA	_
23-21	4595-4596	)	_
23-22	4597-4601	with	_
23-23	4602-4604	an	_
23-24	4605-4614	8-channel	_
23-25	4615-4619	head	_
23-26	4620-4624	coil	_
23-27	4625-4626	.	_

24-1	4627-4630	The	_
24-2	4631-4639	mcDESPOT	_
24-3	4640-4648	protocol	_
24-4	4649-4658	consisted	_
24-5	4659-4661	of	_
24-6	4662-4663	a	_
24-7	4664-4671	spoiled	_
24-8	4672-4680	gradient	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
24-9	4681-4689	recalled	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
24-10	4690-4694	echo	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
24-11	4695-4696	(	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
24-12	4697-4701	SPGR	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
24-13	4702-4703	)	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
24-14	4704-4712	sequence	_
24-15	4713-4719	across	_
24-16	4720-4724	nine	_
24-17	4725-4729	flip	_
24-18	4730-4736	angles	_
24-19	4737-4738	α	_
24-20	4739-4740	(	_
24-21	4741-4743	TR	_
24-22	4744-4745	=	_
24-23	4746-4749	8.0	_
24-24	4750-4752	ms	_
24-25	4753-4754	;	_
24-26	4755-4757	TE	_
24-27	4758-4759	=	_
24-28	4760-4763	3.6	_
24-29	4764-4766	ms	_
24-30	4767-4768	;	_
24-31	4769-4770	α	_
24-32	4771-4772	=	_
24-33	4773-4774	[	_
24-34	4775-4776	2	_
24-35	4777-4778	,	_
24-36	4779-4780	3	_
24-37	4781-4782	,	_
24-38	4783-4784	4	_
24-39	4785-4786	,	_
24-40	4787-4788	5	_
24-41	4789-4790	,	_
24-42	4791-4792	6	_
24-43	4793-4794	,	_
24-44	4795-4796	7	_
24-45	4797-4798	,	_
24-46	4799-4800	9	_
24-47	4801-4802	,	_
24-48	4803-4805	13	_
24-49	4806-4807	,	_
24-50	4808-4810	18	_
24-51	4811-4812	]	_
24-52	4813-4814	°	_
24-53	4815-4816	;	_
24-54	4817-4823	matrix	_
24-55	4824-4825	=	_
24-56	4826-4829	128	_
24-57	4830-4831	×	_
24-58	4832-4835	128	_
24-59	4836-4837	)	_
24-60	4838-4839	,	_
24-61	4840-4843	and	_
24-62	4844-4845	a	_
24-63	4846-4854	balanced	_
24-64	4855-4867	steady-state	_
24-65	4868-4872	free	_
24-66	4873-4883	procession	_
24-67	4884-4885	(	_
24-68	4886-4891	bSSFP	_
24-69	4892-4893	)	_
24-70	4894-4902	sequence	_
24-71	4903-4909	across	_
24-72	4910-4915	eight	_
24-73	4916-4920	flip	_
24-74	4921-4927	angles	_
24-75	4928-4929	,	_
24-76	4930-4938	acquired	_
24-77	4939-4941	at	_
24-78	4942-4956	radiofrequency	_
24-79	4957-4962	phase	_
24-80	4963-4970	cycling	_
24-81	4971-4979	patterns	_
24-82	4980-4982	of	_
24-83	4983-4985	0°	_
24-84	4986-4989	and	_
24-85	4990-4994	180°	_
24-86	4995-4997	to	_
24-87	4998-5005	correct	_
24-88	5006-5009	for	_
24-89	5010-5023	off-resonance	_
24-90	5024-5031	effects	_
24-91	5032-5033	(	_
24-92	5034-5036	TR	_
24-93	5037-5038	=	_
24-94	5039-5042	3.8	_
24-95	5043-5045	ms	_
24-96	5046-5047	;	_
24-97	5048-5050	TE	_
24-98	5051-5052	=	_
24-99	5053-5056	1.9	_
24-100	5057-5059	ms	_
24-101	5060-5061	;	_
24-102	5062-5063	α	_
24-103	5064-5065	=	_
24-104	5066-5067	[	_
24-105	5068-5070	12	_
24-106	5071-5072	,	_
24-107	5073-5075	16	_
24-108	5076-5077	,	_
24-109	5078-5080	21	_
24-110	5081-5082	,	_
24-111	5083-5085	27	_
24-112	5086-5087	,	_
24-113	5088-5090	33	_
24-114	5091-5092	,	_
24-115	5093-5095	40	_
24-116	5096-5097	,	_
24-117	5098-5100	51	_
24-118	5101-5102	,	_
24-119	5103-5105	68	_
24-120	5106-5107	]	_
24-121	5108-5109	;	_
24-122	5110-5116	matrix	_
24-123	5117-5118	=	_
24-124	5119-5122	128	_
24-125	5123-5124	×	_
24-126	5125-5128	128	_
24-127	5129-5130	)	_
24-128	5131-5132	.	_

25-1	5133-5135	In	_
25-2	5136-5144	addition	_
25-3	5145-5147	an	_
25-4	5148-5157	inversion	_
25-5	5158-5166	recovery	_
25-6	5167-5171	SPGR	_
25-7	5172-5175	was	_
25-8	5176-5184	acquired	_
25-9	5185-5188	for	_
25-10	5189-5199	estimating	_
25-11	5200-5203	the	_
25-12	5204-5208	flip	_
25-13	5209-5214	angle	_
25-14	5215-5220	error	_
25-15	5221-5227	caused	_
25-16	5228-5230	by	_
25-17	5231-5243	transmitting	_
25-18	5244-5246	B1	_
25-19	5247-5252	field	_
25-20	5253-5266	inhomogeneity	_
25-21	5267-5268	(	_
25-22	5269-5271	TR	_
25-23	5272-5273	=	_
25-24	5274-5277	8.0	_
25-25	5278-5280	ms	_
25-26	5281-5282	;	_
25-27	5283-5285	TE	_
25-28	5286-5287	=	_
25-29	5288-5291	3.6	_
25-30	5292-5294	ms	_
25-31	5295-5296	;	_
25-32	5297-5298	α	_
25-33	5299-5300	=	_
25-34	5301-5303	5°	_
25-35	5304-5305	;	_
25-36	5306-5312	matrix	_
25-37	5313-5314	=	_
25-38	5315-5318	220	_
25-39	5319-5320	×	_
25-40	5321-5324	110	_
25-41	5325-5326	)	_
25-42	5327-5328	.	_

26-1	5329-5332	The	_
26-2	5333-5338	field	_
26-3	5339-5341	of	_
26-4	5342-5346	view	_
26-5	5347-5350	was	_
26-6	5351-5354	220	_
26-7	5355-5356	×	_
26-8	5357-5360	220	_
26-9	5361-5363	cm	_
26-10	5364-5367	and	_
26-11	5368-5371	the	_
26-12	5372-5377	voxel	_
26-13	5378-5382	size	_
26-14	5383-5386	was	_
26-15	5387-5390	1.7	_
26-16	5391-5393	mm	_
26-17	5394-5403	isotropic	_
26-18	5404-5405	.	_

27-1	5406-5409	The	_
27-2	5410-5414	full	_
27-3	5415-5423	mcDESPOT	_
27-4	5424-5432	sequence	_
27-5	5433-5439	lasted	_
27-6	5440-5453	approximately	_
27-7	5454-5456	13	_
27-8	5457-5460	min	_
27-9	5461-5462	.	_

28-1	5463-5466	All	_
28-2	5467-5470	raw	_
28-3	5471-5477	images	_
28-4	5478-5482	were	_
28-5	5483-5491	visually	_
28-6	5492-5501	inspected	_
28-7	5502-5505	for	_
28-8	5506-5512	motion	_
28-9	5513-5522	artefacts	_
28-10	5523-5524	.	_

29-1	5525-5537	Participants	_
29-2	5538-5542	with	_
29-3	5543-5550	missing	_
29-4	5551-5556	scans	_
29-5	5557-5559	or	_
29-6	5560-5569	excessive	_
29-7	5570-5576	motion	_
29-8	5577-5581	were	_
29-9	5582-5592	re-scanned	_
29-10	5593-5599	either	_
29-11	5600-5611	immediately	_
29-12	5612-5614	or	_
29-13	5615-5617	at	_
29-14	5618-5623	their	_
29-15	5624-5632	earliest	_
29-16	5633-5644	convenience	_
29-17	5645-5646	,	_
29-18	5647-5656	resulting	_
29-19	5657-5659	in	_
29-20	5660-5661	a	_
29-21	5662-5670	complete	_
29-22	5671-5678	dataset	_
29-23	5679-5680	.	_

30-1	5681-5685	Each	_
30-2	5686-5693	subject	_
30-3	5694-5696	's	_
30-4	5697-5702	scans	_
30-5	5703-5707	were	_
30-6	5708-5716	linearly	_
30-7	5717-5729	coregistered	_
30-8	5730-5731	,	_
30-9	5732-5735	and	_
30-10	5736-5745	non-brain	_
30-11	5746-5756	parenchyma	_
30-12	5757-5763	signal	_
30-13	5764-5771	removed	_
30-14	5772-5777	using	_
30-15	5778-5781	BET	_
30-16	5782-5783	(	_
30-17	5784-5789	FMRIB	_
30-18	5790-5798	Software	_
30-19	5799-5806	Library	_
30-20	5807-5808	,	_
30-21	5809-5831	www.fmrib.ox.ac.uk/fsl	_
30-22	5832-5833	)	_
30-23	5834-5835	.	_

31-1	5836-5844	mcDESPOT	_
31-2	5845-5849	maps	_
31-3	5850-5854	were	_
31-4	5855-5864	processed	_
31-5	5865-5870	using	_
31-6	5871-5874	our	_
31-7	5875-5885	previously	_
31-8	5886-5895	described	_
31-9	5896-5907	open-source	_
31-10	5908-5916	software	_
31-11	5917-5918	.	_

32-1	5919-5926	Briefly	_
32-2	5927-5928	,	_
32-3	5929-5934	first	_
32-4	5935-5937	T1	_
32-5	5938-5939	&	_
32-6	5940-5942	B1	_
32-7	5943-5947	maps	_
32-8	5948-5952	were	_
32-9	5953-5963	calculated	_
32-10	5964-5968	from	_
32-11	5969-5972	the	_
32-12	5973-5977	data	_
32-13	5978-5979	,	_
32-14	5980-5984	then	_
32-15	5985-5987	T2	_
32-16	5988-5989	&	_
32-17	5990-6003	off-resonance	_
32-18	6004-6008	maps	_
32-19	6009-6010	,	_
32-20	6011-6014	and	_
32-21	6015-6019	then	_
32-22	6020-6027	finally	_
32-23	6028-6034	Myelin	_
32-24	6035-6040	Water	_
32-25	6041-6049	Fraction	_
32-26	6050-6054	maps	_
32-27	6055-6060	using	_
32-28	6061-6062	a	_
32-29	6063-6068	three	_
32-30	6069-6078	component	_
32-31	6079-6084	model	_
32-32	6085-6088	and	_
32-33	6089-6097	Gaussian	_
32-34	6098-6104	Region	_
32-35	6105-6116	Contraction	_
32-36	6117-6118	.	_

33-1	6119-6122	MWF	_
33-2	6123-6127	maps	_
33-3	6128-6132	were	_
33-4	6133-6145	non-linearly	_
33-5	6146-6156	registered	_
33-6	6157-6159	to	_
33-7	6160-6163	the	_
33-8	6164-6170	MNI152	_
33-9	6171-6172	2	_
33-10	6173-6175	mm	_
33-11	6176-6185	isotropic	_
33-12	6186-6194	standard	_
33-13	6195-6200	brain	_
33-14	6201-6202	,	_
33-15	6203-6206	and	_
33-16	6207-6215	smoothed	_
33-17	6216-6221	using	_
33-18	6222-6223	a	_
33-19	6224-6232	Gaussian	_
33-20	6233-6239	kernel	_
33-21	6240-6242	at	_
33-22	6243-6244	5	_
33-23	6245-6247	mm	_
33-24	6248-6252	FWHM	_
33-25	6253-6254	.	_

34-1	6255-6266	Statistical	_
34-2	6267-6275	analysis	_
34-3	6276-6287	Whole-brain	_
34-4	6288-6293	group	_
34-5	6294-6305	comparisons	_
34-6	6306-6317	Whole-brain	_
34-7	6318-6328	normalised	_
34-8	6329-6332	MWF	_
34-9	6333-6337	maps	_
34-10	6338-6342	were	_
34-11	6343-6352	subjected	_
34-12	6353-6355	to	_
34-13	6356-6370	non-parametric	_
34-14	6371-6382	permutation	_
34-15	6383-6388	tests	_
34-16	6389-6394	using	_
34-17	6395-6398	FSL	_
34-18	6399-6401	's	_
34-19	6402-6411	randomise	_
34-20	6412-6413	(	_
34-21	6414-6418	with	_
34-22	6419-6425	10,000	_
34-23	6426-6438	permutations	_
34-24	6439-6440	)	_
34-25	6441-6442	,	_
34-26	6443-6446	and	_
34-27	6447-6459	significance	_
34-28	6460-6466	values	_
34-29	6467-6471	were	_
34-30	6472-6481	corrected	_
34-31	6482-6485	for	_
34-32	6486-6494	multiple	_
34-33	6495-6506	comparisons	_
34-34	6507-6512	using	_
34-35	6513-6527	threshold-free	_
34-36	6528-6535	cluster	_
34-37	6536-6547	enhancement	_
34-38	6548-6549	(	_
34-39	6550-6554	TFCE	_
34-40	6555-6556	)	_
34-41	6557-6558	.	_

35-1	6559-6567	Clusters	_
35-2	6568-6572	were	_
35-3	6573-6580	defined	_
35-4	6581-6585	with	_
35-5	6586-6588	an	_
35-6	6589-6595	extent	_
35-7	6596-6605	threshold	_
35-8	6606-6608	of	_
35-9	6609-6611	50	_
35-10	6612-6618	voxels	_
35-11	6619-6620	.	_

36-1	6621-6623	We	_
36-2	6624-6630	tested	_
36-3	6631-6634	the	_
36-4	6635-6641	effect	_
36-5	6642-6644	of	_
36-6	6645-6650	group	_
36-7	6651-6652	(	_
36-8	6653-6655	HC	_
36-9	6656-6659	vs.	_
36-10	6660-6663	NTR	_
36-11	6664-6667	vs.	_
36-12	6668-6671	TRS	_
36-13	6672-6673	)	_
36-14	6674-6675	,	_
36-15	6676-6685	adjusting	_
36-16	6686-6689	for	_
36-17	6690-6697	effects	_
36-18	6698-6700	of	_
36-19	6701-6704	age	_
36-20	6705-6708	and	_
36-21	6709-6712	sex	_
36-22	6713-6714	.	_

37-1	6715-6720	White	_
37-2	6721-6727	matter	_
37-3	6728-6737	histogram	_
37-4	6738-6746	analysis	_
37-5	6747-6749	In	_
37-6	6750-6755	order	_
37-7	6756-6758	to	_
37-8	6759-6766	analyse	_
37-9	6767-6770	the	_
37-10	6771-6783	distribution	_
37-11	6784-6786	of	_
37-12	6787-6790	WMF	_
37-13	6791-6797	values	_
37-14	6798-6804	within	_
37-15	6805-6808	the	_
37-16	6809-6814	white	_
37-17	6815-6821	matter	_
37-18	6822-6834	specifically	_
37-19	6835-6836	,	_
37-20	6837-6839	we	_
37-21	6840-6848	overlaid	_
37-22	6849-6852	MWF	_
37-23	6853-6857	maps	_
37-24	6858-6862	with	_
37-25	6863-6864	a	_
37-26	6865-6870	white	_
37-27	6871-6877	matter	_
37-28	6878-6882	mask	_
37-29	6883-6891	obtained	_
37-30	6892-6896	from	_
37-31	6897-6900	the	_
37-32	6901-6906	Johns	_
37-33	6907-6914	Hopkins	_
37-34	6915-6925	University	_
37-35	6926-6931	White	_
37-36	6932-6938	Matter	_
37-37	6939-6944	Atlas	_
37-38	6945-6946	.	_

38-1	6947-6956	Histogram	_
38-2	6957-6965	analyses	_
38-3	6966-6968	of	_
38-4	6969-6974	white	_
38-5	6975-6981	matter	_
38-6	6982-6985	MWF	_
38-7	6986-6990	were	_
38-8	6991-7000	conducted	_
38-9	7001-7003	by	_
38-10	7004-7011	summing	_
38-11	7012-7015	the	_
38-12	7016-7022	number	_
38-13	7023-7025	of	_
38-14	7026-7032	voxels	_
38-15	7033-7036	for	_
38-16	7037-7040	100	_
38-17	7041-7048	uniform	_
38-18	7049-7053	bins	_
38-19	7054-7061	between	_
38-20	7062-7063	0	_
38-21	7064-7065	%	_
38-22	7066-7069	and	_
38-23	7070-7072	30	_
38-24	7073-7074	%	_
38-25	7075-7076	.	_

39-1	7077-7081	Each	_
39-2	7082-7092	individual	_
39-3	7093-7095	's	_
39-4	7096-7105	histogram	_
39-5	7106-7109	was	_
39-6	7110-7120	normalised	_
39-7	7121-7125	with	_
39-8	7126-7133	respect	_
39-9	7134-7136	to	_
39-10	7137-7140	the	_
39-11	7141-7145	area	_
39-12	7146-7148	of	_
39-13	7149-7152	the	_
39-14	7153-7162	histogram	_
39-15	7163-7164	.	_

40-1	7165-7168	For	_
40-2	7169-7173	each	_
40-3	7174-7181	subject	_
40-4	7182-7183	,	_
40-5	7184-7187	the	_
40-6	7188-7192	mean	_
40-7	7193-7194	(	_
40-8	7195-7200	first	_
40-9	7201-7207	moment	_
40-10	7208-7209	)	_
40-11	7210-7211	,	_
40-12	7212-7220	variance	_
40-13	7221-7222	(	_
40-14	7223-7229	second	_
40-15	7230-7236	moment	_
40-16	7237-7238	)	_
40-17	7239-7240	,	_
40-18	7241-7245	peak	_
40-19	7246-7254	position	_
40-20	7255-7256	(	_
40-21	7257-7261	mode	_
40-22	7262-7263	)	_
40-23	7264-7265	,	_
40-24	7266-7269	and	_
40-25	7270-7274	peak	_
40-26	7275-7281	height	_
40-27	7282-7283	(	_
40-28	7284-7293	frequency	_
40-29	7294-7296	of	_
40-30	7297-7303	voxels	_
40-31	7304-7306	in	_
40-32	7307-7310	the	_
40-33	7311-7316	modal	_
40-34	7317-7320	bin	_
40-35	7321-7322	)	_
40-36	7323-7325	of	_
40-37	7326-7329	the	_
40-38	7330-7339	histogram	_
40-39	7340-7344	were	_
40-40	7345-7355	calculated	_
40-41	7356-7359	and	_
40-42	7360-7372	subsequently	_
40-43	7373-7381	compared	_
40-44	7382-7389	between	_
40-45	7390-7396	groups	_
40-46	7397-7402	using	_
40-47	7403-7417	non-parametric	_
40-48	7418-7425	Kruskal	_
40-49	7426-7432	Wallis	_
40-50	7433-7438	tests	_
40-51	7439-7440	.	_

41-1	7441-7444	MWF	http://maven.renci.org/NeuroBridge/neurobridge#Thing
41-2	7445-7448	and	_
41-3	7449-7452	the	_
41-4	7453-7459	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
41-5	7460-7466	effect	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
41-6	7467-7473	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
41-7	7474-7478	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
41-8	7479-7487	Subjects	_
41-9	7488-7497	performed	_
41-10	7498-7499	a	_
41-11	7500-7508	standard	_
41-12	7509-7515	verbal	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask
41-13	7516-7522	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask
41-14	7523-7527	task	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask
41-15	7528-7534	inside	_
41-16	7535-7538	the	_
41-17	7539-7542	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-18	7543-7550	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-19	7551-7552	.	_

42-1	7553-7556	The	_
42-2	7557-7561	task	_
42-3	7562-7571	consisted	_
42-4	7572-7574	of	_
42-5	7575-7581	naming	_
42-6	7582-7585	the	_
42-7	7586-7590	font	_
42-8	7591-7597	colour	_
42-9	7598-7600	of	_
42-10	7601-7607	colour	_
42-11	7608-7613	words	_
42-12	7614-7618	that	_
42-13	7619-7623	were	_
42-14	7624-7630	either	_
42-15	7631-7640	congruent	_
42-16	7641-7642	(	_
42-17	7643-7646	e.g	_
42-18	7647-7648	.	_

43-1	7649-7652	the	_
43-2	7653-7657	word	_
43-3	7658-7659	“	_
43-4	7660-7666	yellow	_
43-5	7667-7668	”	_
43-6	7669-7676	printed	_
43-7	7677-7679	in	_
43-8	7680-7686	yellow	_
43-9	7687-7688	)	_
43-10	7689-7691	or	_
43-11	7692-7703	incongruent	_
43-12	7704-7705	(	_
43-13	7706-7709	e.g	_
43-14	7710-7711	.	_

44-1	7712-7715	the	_
44-2	7716-7720	word	_
44-3	7721-7722	‘	_
44-4	7723-7729	yellow	_
44-5	7730-7731	’	_
44-6	7732-7739	printed	_
44-7	7740-7742	in	_
44-8	7743-7747	blue	_
44-9	7748-7749	)	_
44-10	7750-7751	.	_

45-1	7752-7764	Thirty-three	_
45-2	7765-7774	congruent	_
45-3	7775-7776	,	_
45-4	7777-7779	33	_
45-5	7780-7791	incongruent	_
45-6	7792-7793	,	_
45-7	7794-7797	and	_
45-8	7798-7800	34	_
45-9	7801-7809	fixation	_
45-10	7810-7816	trials	_
45-11	7817-7821	were	_
45-12	7822-7831	presented	_
45-13	7832-7834	in	_
45-14	7835-7845	randomised	_
45-15	7846-7851	order	_
45-16	7852-7853	,	_
45-17	7854-7858	each	_
45-18	7859-7863	with	_
45-19	7864-7865	a	_
45-20	7866-7874	duration	_
45-21	7875-7877	of	_
45-22	7878-7881	700	_
45-23	7882-7884	ms	_
45-24	7885-7888	and	_
45-25	7889-7912	inter-stimulus-interval	_
45-26	7913-7915	of	_
45-27	7916-7920	2300	_
45-28	7921-7923	ms	_
45-29	7924-7925	.	_

46-1	7926-7930	This	_
46-2	7931-7939	preceded	_
46-3	7940-7943	the	_
46-4	7944-7952	mcDESPOT	_
46-5	7953-7961	scanning	_
46-6	7962-7970	protocol	_
46-7	7971-7972	.	_

47-1	7973-7977	Each	_
47-2	7978-7985	subject	_
47-3	7986-7988	's	_
47-4	7989-7995	Stroop	_
47-5	7996-8002	effect	_
47-6	8003-8006	was	_
47-7	8007-8014	defined	_
47-8	8015-8017	as	_
47-9	8018-8021	the	_
47-10	8022-8032	difference	_
47-11	8033-8040	between	_
47-12	8041-8046	their	_
47-13	8047-8051	mean	_
47-14	8052-8060	reaction	_
47-15	8061-8065	time	_
47-16	8066-8067	(	_
47-17	8068-8070	RT	_
47-18	8071-8072	)	_
47-19	8073-8075	on	_
47-20	8076-8087	incongruent	_
47-21	8088-8094	trials	_
47-22	8095-8098	and	_
47-23	8099-8104	their	_
47-24	8105-8109	mean	_
47-25	8110-8112	RT	_
47-26	8113-8115	on	_
47-27	8116-8125	congruent	_
47-28	8126-8132	trials	_
47-29	8133-8134	.	_

48-1	8135-8138	The	_
48-2	8139-8145	Stroop	_
48-3	8146-8152	effect	_
48-4	8153-8156	was	_
48-5	8157-8165	compared	_
48-6	8166-8173	between	_
48-7	8174-8180	groups	_
48-8	8181-8186	using	_
48-9	8187-8194	one-way	_
48-10	8195-8200	ANOVA	_
48-11	8201-8202	.	_

49-1	8203-8205	We	_
49-2	8206-8212	tested	_
49-3	8213-8216	for	_
49-4	8217-8229	correlations	_
49-5	8230-8237	between	_
49-6	8238-8249	whole-brain	_
49-7	8250-8253	MWF	_
49-8	8254-8257	and	_
49-9	8258-8261	the	_
49-10	8262-8264	RT	_
49-11	8265-8271	Stroop	_
49-12	8272-8278	effect	_
49-13	8279-8285	across	_
49-14	8286-8289	all	_
49-15	8290-8298	subjects	_
49-16	8299-8304	using	_
49-17	8305-8314	randomise	_
49-18	8315-8316	.	_

50-1	8317-8320	For	_
50-2	8321-8324	the	_
50-3	8325-8334	resulting	_
50-4	8335-8346	significant	_
50-5	8347-8354	cluster	_
50-6	8355-8356	,	_
50-7	8357-8359	we	_
50-8	8360-8369	extracted	_
50-9	8370-8374	each	_
50-10	8375-8382	subject	_
50-11	8383-8385	's	_
50-12	8386-8390	mean	_
50-13	8391-8394	MWF	_
50-14	8395-8398	and	_
50-15	8399-8407	compared	_
50-16	8408-8413	these	_
50-17	8414-8421	between	_
50-18	8422-8428	groups	_
50-19	8429-8430	.	_

51-1	8431-8433	We	_
51-2	8434-8438	then	_
51-3	8439-8448	conducted	_
51-4	8449-8450	a	_
51-5	8451-8460	mediation	_
51-6	8461-8469	analysis	_
51-7	8470-8472	to	_
51-8	8473-8477	test	_
51-9	8478-8485	whether	_
51-10	8486-8489	MWF	_
51-11	8490-8492	in	_
51-12	8493-8497	this	_
51-13	8498-8504	region	_
51-14	8505-8513	mediated	_
51-15	8514-8519	group	_
51-16	8520-8531	differences	_
51-17	8532-8534	in	_
51-18	8535-8538	the	_
51-19	8539-8541	RT	_
51-20	8542-8548	Stroop	_
51-21	8549-8555	effect	_
51-22	8556-8557	.	_

52-1	8558-8560	We	_
52-2	8561-8565	used	_
52-3	8566-8567	a	_
52-4	8568-8577	bootstrap	_
52-5	8578-8586	approach	_
52-6	8587-8595	proposed	_
52-7	8596-8598	by	_
52-8	8599-8601	in	_
52-9	8602-8607	order	_
52-10	8608-8610	to	_
52-11	8611-8615	test	_
52-12	8616-8619	for	_
52-13	8620-8632	significance	_
52-14	8633-8635	of	_
52-15	8636-8639	the	_
52-16	8640-8648	indirect	_
52-17	8649-8655	effect	_
52-18	8656-8658	of	_
52-19	8659-8664	group	_
52-20	8665-8667	on	_
52-21	8668-8670	RT	_
52-22	8671-8677	Stroop	_
52-23	8678-8684	effect	_
52-24	8685-8686	.	_

